International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases最新文献

{"title":"Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection.","authors":"Weeraya Phaisal,&nbsp;Watsamon Jantarabenjakul,&nbsp;Noppadol Wacharachaisurapol,&nbsp;Monta Tawan,&nbsp;Thanyawee Puthanakit,&nbsp;Supeecha Wittayalertpanya,&nbsp;Pajaree Chariyavilaskul","doi":"10.1016/j.ijid.2022.07.040","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.07.040","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated the steady-state pharmacokinetic profiles of 3-month weekly rifapentine plus isoniazid (3HP) in children with latent tuberculosisinfection (LTBI). We also assessed other factors, including tablet integrity, food, and pharmacogenetics.</p><p><strong>Methods: </strong>During the 3HP treatment, blood and urine samples were collected in week 4. Isoniazid and rifapentine levels were measured using a high-performance liquid chromatography technique. The genetic variation of arylamine N-acetyltransferase 2 (NAT2) and arylacetamide deacetylase (AADAC) were assessed by the MassARRAY®. Safety and clinical outcomes at week 48 were monitored.</p><p><strong>Results: </strong>A total of 12 children with LTBI (age 3.8 [range 2.1-4.9 years old]) completed the treatment (isoniazid and rifapentine dose 25.0 [range 21.7-26.8] and 25.7 [range 20.7-32.1] mg/kg, respectively). No serious adverse events or active TB occurred. Tablet integrity was associated with decreased area under the concentration-time curve (91 vs 73 mg.h/l, P= 0.026) and increased apparent oral clearance of isoniazid (0.27 vs 0.32 l/h/kg, P= 0.019) and decreased rifapentine's renal clearance (CL_R, 0.005 vs 0.003 l/h, P= 0.014). Food was associated with increased CL_R of isoniazid (3.45 vs 8.95 l/h, P= 0.006) but not rifapentine. Variability in NAT2 and AADAC did not affect the pharmacokinetics of both drugs.</p><p><strong>Conclusion: </strong>There is high variability in the pharmacokinetic profiles of isoniazid and rifapentine in young children with LTBI. The variability was partly influenced by tablet integrity and food, but not pharmacogenetics. Further study in a larger cohort is warranted to display the relationship of these factors to treatment outcomes.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"725-732"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological characteristics of Lassa fever cases in Liberia: a retrospective analysis of surveillance data, 2019-2020.","authors":"Ralph Weah Jetoh,&nbsp;Shruti Malik,&nbsp;Bode Shobayo,&nbsp;Fahn Taweh,&nbsp;Trokon Omarley Yeabah,&nbsp;Josiah George,&nbsp;Burgess Gbelee,&nbsp;Julius Teahton,&nbsp;Francis Jaryan,&nbsp;Momo Tegli,&nbsp;Chukwuma David Umeokonkwo,&nbsp;Jane MaCauley","doi":"10.1016/j.ijid.2022.07.006","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.07.006","url":null,"abstract":"<p><strong>Objectives: </strong>Liberia is endemic to Lassa fever (LF) and has the largest reported per capita incidence of LF patients in the West African region. Cases of the disease increased unprecedentedly in 2019 and 2020, characterized by a geographical drift in epidemiology and seasonal variation of occurrence. This study aims to describe the epidemiological and clinical characteristics of LF in Liberia from 2019 to 2020.</p><p><strong>Methods: </strong>A retrospective study was conducted on cases of LF confirmed at the National Public Health Reference Laboratory from January 2019 to December 2020. Medical records were reviewed, and epidemiological and clinical data were collected in an organized manner. Descriptive and inferential statistics were carried out using Epi Info (version 7.2.5.0).</p><p><strong>Results: </strong>A total of 382 suspected LF cases were reported, of which 103 were laboratory-confirmed, yielding a case positivity rate of 27% (103/382). The median age of the LF cases was 20 (IQR: 9-30). Children younger than 18 years accounted for 40.8% (42/103) of the cases and healthcare workers' cases constituted 7.7% of the cases. Bong, Nimba, and Grand Bass accounted for 87.4% of the cases with cases in new counties like Lofa, Margibi, and Grand Kru. Hemorrhage (aOR:10.2; 95% CI: 3.11-33.81), patients who did not receive ribavirin (aOR: 4.4; 95% CI: 1.12-17.57, P = 0.034), and patients aged 40 years or older (aOR: 6.2; 95% CI: 1.19-32.53, P = 0.049) were associated with LF mortality.</p><p><strong>Conclusion: </strong>The LF cases in 2019 and 2020 had a high case fatality rate and spread to new counties that had not previously reported LF. The disease occurred during most of the rainy season instead of the usual dry season. There is an urgent need to lower morbidity and mortality, improve early presentation to the hospital, and early initiation of appropriate medical care.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"767-774"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40581806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caution when using 1,3, β-D-glucan in the CSF as a biomarker of Candida albicans meningitis.","authors":"Laura Barbolini,&nbsp;Arnaud Riat,&nbsp;Christian Van Delden,&nbsp;Jacques Schrenzel","doi":"10.1016/j.ijid.2022.06.033","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.06.033","url":null,"abstract":"<p><p>Relying on a biomarker to diagnose or follow up the treatment of a Candida albicans meningitis would have an impact on patient management. The biomarker 1,3, β-D-glucan (BDG), developed for serum testing, shows inconsistent values when applied on cerebrospinal fluid (CSF), and its use with the current protocol on CSF samples warrants caution.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"531-533"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40400438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV-1 Subtype Shift in the Philippines is Associated With High Transmitted Drug Resistance, High Viral Loads, and Fast Immunologic Decline.","authors":"Edsel Maurice T Salvaña,&nbsp;Niña Theresa Dungca,&nbsp;Geraldine Arevalo,&nbsp;Kingbherly Li,&nbsp;Christian Francisco,&nbsp;Christine Penalosa,&nbsp;Angelo Dela Tonga,&nbsp;Katerina Leyritana,&nbsp;Rontgene Solante,&nbsp;Rosario Jessica Tactacan-Abrenica,&nbsp;Jodor Lim,&nbsp;Marissa Alejandria,&nbsp;Noel Palaypayon,&nbsp;Brian Schwem","doi":"10.1016/j.ijid.2022.06.048","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.06.048","url":null,"abstract":"<p><strong>Objectives: </strong>The Philippines has one of the fastest growing HIV epidemics in the world. A subtype shift from B to CRF01_AE may have contributed to the increase in cases. We undertook a genotyping and transmitted drug resistance (TDR) study to determine if the dominant subtype has any advantages in resistance and transmission.</p><p><strong>Methods: </strong>Filipinos who were treatment-naive who were living with HIV were recruited from two large government treatment hubs from March 2016 to August 2018. HIV-1 viral load, CD4 count, genotyping, and TDR testing were performed. Demographic and clinical data were collected and compared across subtypes.</p><p><strong>Results: </strong>A total of 298 Filipinos living with HIV were recruited. Median CD4 count was 143 cells/µl and HIV viral load was 2,345,431 copies/ml. Sanger-based sequencing showed 230/298 (77.2%) had subtype CRF01_AE, 41 (13.8%) subtype B, and the rest had other subtypes or recombinants. Overall TDR was 11.7%. TDR was associated with lower viral loads and no previous HIV testing. CRF01_AE had a higher likelihood of a viral load >100,000 copies/ml and having a baseline CD4 count <50 cells/mm³.</p><p><strong>Conclusion: </strong>TDR in the Philippines is high at 11.7%. CRF01_AE was observed to have a higher baseline viral load and lower CD4 counts compared with other cocirculating subtypes. Further research needs to confirm this observation because it suggests that CRF01_AE may have a survival advantage that led to replacement of subtype B as the dominant subtype. Drug resistance testing is recommended in the Philippines when initiating NNRTI-based antiretroviral therapy but may not be necessary for INSTI-based regimens.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"936-943"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40481017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ceftriaxone-induced encephalopathy in a patient with a solitary kidney.","authors":"Yuya Futagi,&nbsp;Yuriko Ito,&nbsp;Junya Nakade,&nbsp;Arimi Fujita,&nbsp;Tsutomu Shimada,&nbsp;Misaki Yoshida,&nbsp;Yoshinori Takahashi,&nbsp;Mitsuhiro Kawano,&nbsp;Takumi Taniguchi,&nbsp;Yoshimichi Sai","doi":"10.1016/j.ijid.2022.07.036","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.07.036","url":null,"abstract":"<p><p>Ceftriaxone (CRO) is a long-acting third-generation cephalosporin antibiotic. We present a case of CRO-induced encephalopathy in an 84-year-old male patient with a solitary right kidney, admitted with bilateral pneumonia and right pyelonephritis. Intravenous CRO (2 g, every 24 hours) was started for the infection, but tonic-clonic seizures of the left face and left upper extremity appeared on the eighth day. To examine the relationship between CRO administration and the seizures, we measured CRO concentrations in the patients' plasma/serum and cerebrospinal fluid. The CRO concentration in blood at the onset of encephalopathy was estimated to have been approximately 60 μg/ml based on a simulation curve. We also calculated the pharmacokinetic parameters after CRO administration. The patient had about one-tenth of the total body clearance and one-third of the volume of distribution compared with healthy adults, and the elimination half-life was about three times longer.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"722-724"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40511123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of teicoplanin in bloodstream infections caused by Enterococcus faecium: posthoc analysis of a nationwide surveillance.","authors":"Soyoung Ha,&nbsp;Kyungmin Huh,&nbsp;Doo Ryeon Chung,&nbsp;Jae-Hoon Ko,&nbsp;Sun Young Cho,&nbsp;Hee Jae Huh,&nbsp;Nam Yong Lee,&nbsp;Cheol-In Kang,&nbsp;Kyong Ran Peck,&nbsp;Jae-Hoon Song","doi":"10.1016/j.ijid.2022.06.029","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.06.029","url":null,"abstract":"<p><strong>Objectives: </strong>Vancomycin and teicoplanin are glycopeptides with activity against Enterococcus faecium. However, studies on the clinical efficacy of teicoplanin are limited. This study aimed to compare the therapeutic efficacy of teicoplanin and vancomycin in E. faecium bacteremia.</p><p><strong>Methods: </strong>We identified patients with bloodstream infections prospectively from July 2015 to December 2016 in 14 hospitals as part of a multicenter nationwide surveillance. Patients with E. faecium monomicrobial bacteremia were selected. Teicoplanin and vancomycin groups included patients treated with either agent for ≥48 hours. The primary outcome was 30-day all-cause in-hospital mortality. The Cox proportional hazards model with inverse probability weighting was used to account for the imbalance in baseline characteristics between the two groups.</p><p><strong>Results: </strong>Among 97 patients with E. faecium bacteremia, 33 (34%) were treated with teicoplanin and 64 (66%) with vancomycin. There were no significant differences in 30-day in-hospital mortality (18.2% vs 26.6%, P = 0.358) and 7-day mortality (6.1% vs 15.6%, P = 0.212). Furthermore, multivariable analysis confirmed that the use of teicoplanin was not significantly associated with mortality (adjusted odds ratio, 0.72; 95% confidence interval, 0.28-1.86; P = 0.494).</p><p><strong>Conclusion: </strong>We found no significant differences in the clinical outcomes. These findings suggest teicoplanin as a useful alternative to vancomycin.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"506-513"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40395644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late presentation of human T-lymphotropic virus type 1 infection in Spain reflects suboptimal testing strategies.","authors":"Carmen de Mendoza,&nbsp;Leire Pérez,&nbsp;Mario Fernández-Ruiz,&nbsp;María José Pena,&nbsp;José Manuel Ramos,&nbsp;Alberto Richart,&nbsp;María Piron,&nbsp;Ariadna Rando,&nbsp;Elisenda Miró,&nbsp;Gabriel Reina,&nbsp;Beatriz Encinas,&nbsp;Silvia Rojo,&nbsp;Antonio Manuel Rodriguez-Iglesias,&nbsp;Rafael Benito,&nbsp;Antonio Aguilera,&nbsp;Ana Treviño,&nbsp;Octavio Corral,&nbsp;Vicente Soriano","doi":"10.1016/j.ijid.2022.07.043","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.07.043","url":null,"abstract":"<p><strong>Objectives: </strong>Although only 10% of persons infected with human T-lymphotropic virus type 1 (HTLV-1) may develop virus-associated illnesses over their lifetime, missing the earlier diagnosis of asymptomatic carriers frequently leads to late presentation.</p><p><strong>Methods: </strong>A nationwide HTLV-1 register was created in Spain in 1989. We examined the main demographics and clinical features at the time of the first diagnosis for more than three decades.</p><p><strong>Results: </strong>A total of 428 individuals infected with HTLV-1 had been reported in Spain until the end of 2021. Up to 96 (22%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (57%), T-cell lymphoma (34%), or Strongyloides stercoralis infestation (8%). Since 2008, HTLV-1 diagnosis has been made at blood banks (44%) or clinics (56%). Native Spaniards and Sub-Saharan Africans are overrepresented among patients presenting with HTLV-1-associated illnesses suggesting that poor epidemiological and/or clinical suspicion, which led to the late presentation are more frequent in them than carriers from Latin America (LATAM) (31.7% vs 20.4%, respectively; P = 0.015).</p><p><strong>Conclusion: </strong>HTLV-1 infection in Spain is frequently diagnosed in patients presenting with characteristic illnesses. Although screening in blood banks mostly identifies asymptomatic carriers from LATAM, a disproportionately high number of Spaniards and Africans are diagnosed too late at the time of clinical manifestations. Expanding testing to all pregnant women and clinics for sexually transmitted infections could help to unveil HTLV-1 asymptomatic carriers.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"970-975"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40555539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Child mortality after the Ebola virus disease outbreak across Guinea, Liberia, and Sierra Leone.","authors":"Young Eun Kim","doi":"10.1016/j.ijid.2022.06.043","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.06.043","url":null,"abstract":"<p><strong>Objectives: </strong>The Ebola virus disease outbreak in 2014-2016 had a substantial impact on population health in Guinea, Liberia, and Sierra Leone. This study aimed to assess whether the impact continued after the outbreak ended regarding child mortality.</p><p><strong>Methods: </strong>Cross-sectional logistic regressions were run using data from the Demographic and Health Surveys in the three countries.</p><p><strong>Results: </strong>The average child mortality rate was significantly lower for children born after the outbreak than for those born before. However, the association of the child mortality rate with an increase in the number of Ebola cases per 100,000 people was significantly stronger for children born after the outbreak ended. Also, the change in the utilization of maternal health services after the outbreak varied across health services.</p><p><strong>Conclusion: </strong>Restoring disrupted child health services to pre-Ebola levels may be more difficult in areas that suffered a higher number of Ebola cases. The recovery of maternal health services after the outbreak might be affected by factors such as the resilience of health systems at the subnational level. This study suggests that strengthening the health system is crucial to fully recover from the Ebola outbreak and cope with future epidemics.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"944-952"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40557861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In reply: the clinical aspect of respiratory management of tetanus with non-invasive positive pressure ventilation.","authors":"Kazuhiro Yasuo","doi":"10.1016/j.ijid.2022.07.011","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.07.011","url":null,"abstract":"","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"602"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40583830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new droplet digital PCR assay: improving detection of paucibacillary smear-negative pulmonary tuberculosis.","authors":"Zhenzhen Zhao,&nbsp;Tao Wu,&nbsp;Minjin Wang,&nbsp;Xiaojuan Chen,&nbsp;Tangyuheng Liu,&nbsp;Yanjun Si,&nbsp;Yanhong Zhou,&nbsp;Binwu Ying","doi":"10.1016/j.ijid.2022.07.041","DOIUrl":"https://doi.org/10.1016/j.ijid.2022.07.041","url":null,"abstract":"<p><strong>Objectives: </strong>Smear-negative pulmonary TB (PTB) is difficult to diagnose. Current diagnosis and treatment monitoring methods have inherent limitations. Droplet digital PCR (ddPCR) is a new technique with high sensitivity. This study presents a novel ddPCR for rapid and sensitive identification of Mycobacterium tuberculosis (MTB).</p><p><strong>Methods: </strong>MTB DNA was detected in respiratory specimens from suspected PTB cases using ddPCR assay, which was directed at two different locations within IS6110. We, for the first time, evaluated the clinical diagnostic ability of this ddPCR for paucibacillary smear-negative PTB.</p><p><strong>Results: </strong>A total of 605 PTB suspects were recruited, including 263 patients with confirmed PTB (84.03% from smear-negative PTB) and 342 without PTB. The sensitivity and specificity of IS6110 ddPCR were 61.22% (95% confidence interval (CI) 55.00-67.10%) and 95.03% (95% CI 92.20-97.10%) for total PTB and 57.92% (95% CI 51.10-64.50%) and 94.57% (95% CI 91.20-96.90%) for smear-negative PTB. ddPCR assay outperformed Xpert MTB/RIF (53.08% vs 28.46%, P = 0.020) in smear-negative PTB detection. Furthermore, effective anti-TB treatment was linked to significantly lower IS6110 copies detected by ddPCR.</p><p><strong>Conclusion: </strong>Herein, we developed and validated a highly sensitive and robust ddPCR assay for MTB quantification in respiratory specimens, which improves diagnosis and therapeutic effect evaluation of smear-negative PTB.</p>","PeriodicalId":505767,"journal":{"name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","volume":" ","pages":"820-828"},"PeriodicalIF":8.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40641030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}